Version 1
: Received: 23 July 2024 / Approved: 24 July 2024 / Online: 24 July 2024 (09:30:18 CEST)
How to cite:
Cavallieri, F.; Lucchi, C.; Grisanti, S.; Monfrini, E.; Fioravanti, V.; Toschi, G.; Di Rauso, G.; Rossi, J.; Di Fonzo, A.; Biagini, G.; Valzania, F. Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?. Preprints2024, 2024071915. https://doi.org/10.20944/preprints202407.1915.v1
Cavallieri, F.; Lucchi, C.; Grisanti, S.; Monfrini, E.; Fioravanti, V.; Toschi, G.; Di Rauso, G.; Rossi, J.; Di Fonzo, A.; Biagini, G.; Valzania, F. Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?. Preprints 2024, 2024071915. https://doi.org/10.20944/preprints202407.1915.v1
Cavallieri, F.; Lucchi, C.; Grisanti, S.; Monfrini, E.; Fioravanti, V.; Toschi, G.; Di Rauso, G.; Rossi, J.; Di Fonzo, A.; Biagini, G.; Valzania, F. Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?. Preprints2024, 2024071915. https://doi.org/10.20944/preprints202407.1915.v1
APA Style
Cavallieri, F., Lucchi, C., Grisanti, S., Monfrini, E., Fioravanti, V., Toschi, G., Di Rauso, G., Rossi, J., Di Fonzo, A., Biagini, G., & Valzania, F. (2024). Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?. Preprints. https://doi.org/10.20944/preprints202407.1915.v1
Chicago/Turabian Style
Cavallieri, F., Giuseppe Biagini and Franco Valzania. 2024 "Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?" Preprints. https://doi.org/10.20944/preprints202407.1915.v1
Abstract
Neurosteroids are pleiotropic molecules involved in various neurodegenerative diseases with neuroinflammation. We assessed neurosteroids serum levels in a cohort of Parkinson’s Disease (PD) patients with heterozygous glucocerebrosidase (GBA) mutations (GBA-PD) compared with matched cohorts of consecutive non-mutated PD (NM-PD) patients, and healthy subjects with (GBA-C) and without (NM-HC) GBA mutations. A consecutive cohort of GBA-PD was paired for age, sex, disease duration, Hoehn & Yahr stage, and comorbidities with a cohort of consecutive NM-PD. Two cohorts of GBA-C and HC were also considered. Clinical assessment included the MDS-UPDRS and the Montreal Cognitive Assessment (MoCA). Serum samples were processed and analyzed by liquid chromatography coupled with triple quadrupole mass spectrometry. Twenty-two GBA-PD (males: 11, age: 63.68), 22 NM-PD (males: 11, age: 63.05), 14 GBA-C (males: 8; age: 49.36), and 15 HC (males: 4; age: 60.60) were studied. Compared to NM-PD, GBA-PD showed more hallucinations and psychosis (p<0.05, Fisher’s exact test) and higher MDS-UPDRS part-II (p<0.05). Most of the serum neurosteroids were reduced in both GBA-PD and NM-PD compared to the respective control cohorts, except for 5α-DHP. Allopregnanolone was the only neurosteroid significantly lower (p<0.01, Dunn’s test) in NM-PD compared to GBA-PD patients. Only in GBA-PD, allopregnanolone, and pregnanolone levels correlated (Spearman) with a more severe MDS-UPDRS part-III. Allopregnanolone levels also negatively correlated with MoCA scores, and pregnanolone levels correlated with more pronounced bradykinesia. This pilot study provides the first observation of changes in neurosteroid peripheral levels in GBA-PD. The involvement of the observed changes in the development of neuropsychological and motor symptoms of GBA-PD deserves further attention.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
